Shares of NuVasive, Inc. (NASDAQ:NUVA) have received an average rating of “Buy” from the sixteen ratings firms that are covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $81.18.

Several brokerages have commented on NUVA. TheStreet raised shares of NuVasive from a “c+” rating to a “b” rating in a research report on Wednesday, May 3rd. Zacks Investment Research upgraded shares of NuVasive from a “sell” rating to a “hold” rating in a report on Thursday, April 27th. BidaskClub upgraded shares of NuVasive from a “hold” rating to a “buy” rating in a report on Wednesday, July 19th. Barclays PLC lifted their price target on shares of NuVasive from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Monday, April 24th. Finally, Royal Bank Of Canada lifted their price target on shares of NuVasive from $76.00 to $85.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 6th.

Shares of NuVasive (NUVA) traded up 4.30% on Friday, hitting $66.63. The company’s stock had a trading volume of 1,695,893 shares. The stock has a 50-day moving average price of $74.06 and a 200 day moving average price of $74.04. NuVasive has a one year low of $56.70 and a one year high of $81.68. The firm has a market cap of $3.39 billion, a price-to-earnings ratio of 104.93 and a beta of 1.06.

NuVasive (NASDAQ:NUVA) last posted its quarterly earnings results on Thursday, July 27th. The medical device company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.02. The business had revenue of $260.60 million during the quarter, compared to analysts’ expectations of $261.95 million. NuVasive had a net margin of 3.50% and a return on equity of 13.04%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.40 EPS. Equities research analysts predict that NuVasive will post $2.00 EPS for the current year.

In other NuVasive news, EVP Peter Michael Leddy bought 7,850 shares of the company’s stock in a transaction on Tuesday, August 1st. The shares were bought at an average cost of $63.88 per share, with a total value of $501,458.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.70% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Westside Investment Management Inc. purchased a new stake in NuVasive during the first quarter worth $109,000. FNY Partners Fund LP bought a new position in shares of NuVasive during the first quarter worth about $112,000. Neuburgh Advisers LLC raised its position in shares of NuVasive by 18.3% in the first quarter. Neuburgh Advisers LLC now owns 1,552 shares of the medical device company’s stock worth $116,000 after buying an additional 240 shares in the last quarter. SpiderRock Advisors LLC bought a new position in shares of NuVasive during the first quarter worth about $124,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in NuVasive by 9.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,901 shares of the medical device company’s stock valued at $146,000 after buying an additional 158 shares during the period.

TRADEMARK VIOLATION NOTICE: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/08/11/nuvasive-inc-nuva-given-average-rating-of-buy-by-analysts-2.html.

About NuVasive

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Analyst Recommendations for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.